CIK 0001279704 · Non-accelerated filer<br>Smaller reporting company
Cellectar Biosciences, Inc.
Sign in to watch- Ticker
- CLRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043321804
- Phone
- (608) 441-8120
- Business address
- 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
- Former names
- NOVELOS THERAPEUTICS, INC., COMMON HORIZONS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 79 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-04 | Elefant Dov Chief Financial Officer | Grant or award · Stock option (right to buy) | +430,000 | 430,000 | ||
| 2021-03-04 | Longcor Jarrod Chief Business Officer | Grant or award · Stock option (right to buy) | +450,000 | 450,000 | ||
| 2021-03-04 | Friend John E. II Chief Medical Officer | Grant or award · Stock option (right to buy) | +330,000 | 330,000 | ||
| 2021-03-04 | CARUSO JAMES V President and CEO | Purchase | +5,100 | $1.70 | $9K | 86,401 |
| 2021-03-04 | CARUSO JAMES V President and CEO | Grant or award · Stock option (right to buy) | +1,600,000 | 1,600,000 | ||
| 2021-03-04 | CARUSO JAMES V President and CEO | Sale · Series A Warrants | +46,948 | $0.19 | $9K | 0 |
| 2020-12-28 | CARUSO JAMES V President and CEO | Purchase | +37,037 | $1.35 | $50K | 81,301 |
| 2020-12-28 | Longcor Jarrod Chief Business Officer | Purchase | +29,630 | $1.35 | $40K | 102,148 |
| 2020-12-28 | Elefant Dov Chief Financial Officer | Purchase | +7,407 | $1.35 | $10K | 11,755 |
| 2020-07-01 | Friend John E. II VP, Chief Medical Officer | Grant or award · Stock option (right to buy) | +100,000 | 100,000 | ||
| 2020-06-24 | Loren Stefan Director | Grant or award · Stock option (right to buy) | +50,000 | 50,000 | ||
| 2020-06-24 | NEIS JOHN Director | Grant or award · Stock option (right to buy) | +50,000 | 50,000 | ||
| 2020-06-24 | HILL STEPHEN A Director | Grant or award · Stock option (right to buy) | +50,000 | 50,000 | ||
| 2020-06-24 | Swirsky Douglas J Director | Grant or award · Stock option (right to buy) | +80,000 | 80,000 | ||
| 2020-06-24 | DRISCOLL FREDERICK W Director | Grant or award · Stock option (right to buy) | +50,000 | 50,000 | ||
| 2020-06-05 | Elefant Dov Chief Financial Officer | Purchase | +4,348 | $1.15 | $5K | 4,348 |
| 2020-06-05 | Elefant Dov Chief Financial Officer | Purchase · Series H Warrants | +2,174 | $0.01 | $22 | 2,174 |
| 2020-06-05 | Longcor Jarrod Chief Business Officer | Purchase | +65,218 | $1.15 | $75K | 72,518 |
| 2020-06-05 | Longcor Jarrod Chief Business Officer | Purchase · Series H Warrants | +32,609 | $0.01 | $326 | 32,609 |
| 2020-06-05 | CARUSO JAMES V President and CEO | Purchase | +21,740 | $1.15 | $25K | 44,264 |
Page 5 of 6 · 117 trades